AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been given an average recommendation of “Hold” by the nine analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $2.20.
Separately, Zacks Investment Research downgraded AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th.
Several large investors have recently modified their holdings of the company. Two Sigma Advisers LP boosted its holdings in shares of AVEO Pharmaceuticals by 7.2% during the fourth quarter. Two Sigma Advisers LP now owns 422,000 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 28,500 shares during the period. Northern Trust Corp boosted its holdings in shares of AVEO Pharmaceuticals by 3.0% during the fourth quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock worth $1,882,000 after acquiring an additional 34,164 shares during the period. HCR Wealth Advisors bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth approximately $28,000. Excalibur Management Corp boosted its holdings in shares of AVEO Pharmaceuticals by 363.6% during the first quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 40,000 shares during the period. Finally, Cetera Advisor Networks LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter worth approximately $38,000. Institutional investors own 27.91% of the company’s stock.
AVEO Pharmaceuticals (NASDAQ:AVEO) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.78 million. AVEO Pharmaceuticals had a negative return on equity of 37.43% and a negative net margin of 46.69%. As a group, equities analysts anticipate that AVEO Pharmaceuticals will post -0.09 EPS for the current fiscal year.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Further Reading: Do Tariffs Work?
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.